Our Networks and Collaborations
We are proud to be involved in a number of collaborations with world class inflammatory research groups. To find out more about our collaborations please follow the links below:
The Manchester Collaborative Centre for Inflammation Research (MCCIR)
The Manchester Collaborative Centre for Inflammation Research (MCCIR) is a partnership between The University of Manchester, GlaxoSmithKline (GSK) and AstraZeneca. This unique collaboration has established a £5m world-leading translational centre for inflammatory diseases.
The collaboration will bring together scientists from the pharmaceutical industry and academia to work collaboratively on inflammation research and translational medicine. The centre will focus on breaking down “research silos” in the pre-competitive phase of drug development. The companies combined with the academic knowledge of The University of Manchester will develop and deliver novel and effective medicines to patients with inflammatory disorders such as arthritis.
This collaboration has expertise in imaging analysis, novel imaging biomarker development and validation. AstraZeneca have invested £0.9M to the alliance over the past five years. Through this alliance the NIHR Manchester Musculoskeletal Biomedical Research Unit is developing novel imaging biomarkers for lupus nephritis and carotid atherosclerotic plaque and DCE-MRI for inflammatory arthritis. For more information please visit the Biomedical Imaging Institute website
NIHR Translational Research Partnership
The TRP group links the NIHR Manchester Musculoskeletal BRU with 30 other NHS Trusts/Universities across the UK under a common collaborative agreement for rapid sign off and delivery of early phase trials and experimental studies. Prof Bruce is the Centre Academic Lead for Manchester and is Deputy Chair of the National Steering Group. Our link to the TRP will allow us to develop new discoveries into early stage trials within the UK and also allows us early access to industry partners with whom to collaborate to bring new medicines to patients as quickly and as safely as possible.
For more information please visit the NIHR website
MRC/ABPI Inflammatory Arthritis Consortium: 'Towards a Cure for Rheumatoid Arthritis' Consortium
This consortium of UK academic rheumatology departments has been funded to establish a new cohort of patients with recent onset inflammatory arthritis and to investigate immunological signatures of active disease which reverse when patients enter remission. We also aim to develop strategies to increase the chances of remission in patients with RA and ultimately to prevent RA occurring in the first place.
The NIHR/WT CRFs are focused on expanding and supporting experimental medicine capacity within Greater Manchester, with a particular focus on several priority areas including musculoskeletal research. The NIHR/WT CRFs will provide support to studies arising from the NIHR Manchester Musculoskeletal BRU and provides a dedicated facility in which BRU studies will take place. The NIHR/WT CRFs have excellent in-patient and out-patient facilities fro adult and children's studies. The Infrastructure within the NIHR/WT CRFs will help facilitate rapid setup and initiation of our programme of research.
To find out more please visit the NIHR/WT CRF website.
CADET is an innovative £3M investment dedicated to developing new drugs to prevent and treat major diseases. The facility opened in 2010 on CMFT site and houses state-of-the-art equipment for analysing tissue and blood samples. Led by Professor Garth Cooper, CADET is the first UK facility to combine a tissue bank with proteomics and metabolomics laboratories on one site. It also has a team of bioinformatics experts who analyse data to identify patterns and trends which could lead to new methods of diagnosis and treatments.
To find out more please visit the CADET website.